AR106536A1 - ANTI-HTRA1 ANTIBODIES AND METHODS OF USE OF THE SAME - Google Patents
ANTI-HTRA1 ANTIBODIES AND METHODS OF USE OF THE SAMEInfo
- Publication number
- AR106536A1 AR106536A1 ARP160103320A ARP160103320A AR106536A1 AR 106536 A1 AR106536 A1 AR 106536A1 AR P160103320 A ARP160103320 A AR P160103320A AR P160103320 A ARP160103320 A AR P160103320A AR 106536 A1 AR106536 A1 AR 106536A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- hvr
- seq
- acid sequence
- htra1
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Reivindicación 1: Un anticuerpo aislado que se une específicamente a un epítopo de HtrA1, donde el epítopo de HtrA1 comprende al menos un aminoácido de la proteína de HtrA1 que se selecciona del grupo que consiste en Arg190, Leu192, Pro193, Phe194 y Arg197 Reivindicación 2: Un anticuerpo aislado que se une específicamente a HtrA1, donde el anticuerpo comprende un dominio de unión que comprende las seis HVR que siguen: (a) HVR-H1 que comprende la secuencia de aminoácidos de DSEX¹H (SEQ ID Nº 1), donde X¹ es Met o Leu; (b) una HVR-H2 que comprende la secuencia de aminoácidos de GVDPETX²GAAYNQKFKG (SEQ ID Nº 2), donde X² es Glu o Asp; (c) una HVR-H3 que comprende la secuencia de aminoácidos de GYDYDYALDY (SEQ ID Nº 3); (d) una HVR-L1 que comprende la secuencia de aminoácidos de RASSSVX³FIH (SEQ ID Nº 4), donde X³ es Glu o Asn; (e) una HVR-L2 que comprende la secuencia de aminoácidos de ATSX⁴LAS (SEQ ID Nº 5), donde X⁴ es Asn, His o Glu; y (f) una HVR-L3 que comprende la secuencia de aminoácidos de QQWX⁵SX⁶PWT (SEQ ID Nº 6), donde X⁵ es Ser o Tyr y X⁶ es Ala o Asn. Reivindicación 22: Un ácido nucleico aislado que codifica el anticuerpo de cualquiera de las reivindicaciones 1 - 21. Reivindicación 24: Una composición farmacéutica que comprende un anticuerpo de cualquiera de las reivindicaciones 1 - 23 y que comprende además al menos un portador, excipiente o diluyente farmacéuticamente aceptable. Reivindicación 39: El método de la reivindicación 38, donde el trastorno asociado a HtrA1 o trastorno ocular es DMAE, retinopatía diabética, retinopatía del prematuro o vasculopatía polipoidea coroidea.Claim 1: An isolated antibody that specifically binds to an HtrA1 epitope, wherein the HtrA1 epitope comprises at least one amino acid of the HtrA1 protein that is selected from the group consisting of Arg190, Leu192, Pro193, Phe194 and Arg197 Claim 2 : An isolated antibody that specifically binds HtrA1, where the antibody comprises a binding domain comprising the six HVRs that follow: (a) HVR-H1 comprising the amino acid sequence of DSEX¹H (SEQ ID No. 1), where X¹ it's Met or Leu; (b) an HVR-H2 comprising the amino acid sequence of GVDPETX²GAAYNQKFKG (SEQ ID No. 2), where X² is Glu or Asp; (c) an HVR-H3 comprising the amino acid sequence of GYDYDYALDY (SEQ ID No. 3); (d) an HVR-L1 comprising the amino acid sequence of RASSSVX³FIH (SEQ ID No. 4), where X³ is Glu or Asn; (e) an HVR-L2 comprising the amino acid sequence of ATSX⁴LAS (SEQ ID No. 5), where X⁴ is Asn, His or Glu; and (f) an HVR-L3 comprising the amino acid sequence of QQWX⁵SX⁶PWT (SEQ ID No. 6), where X⁵ is Ser or Tyr and X⁶ is Ala or Asn. Claim 22: An isolated nucleic acid encoding the antibody of any of claims 1-21. Claim 24: A pharmaceutical composition comprising an antibody of any of claims 1-23 and further comprising at least one carrier, excipient or diluent pharmaceutically acceptable. Claim 39: The method of claim 38, wherein the disorder associated with HtrA1 or ocular disorder is AMD, diabetic retinopathy, retinopathy of prematurity or choroidal polypoid vasculopathy.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562248871P | 2015-10-30 | 2015-10-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106536A1 true AR106536A1 (en) | 2018-01-24 |
Family
ID=61159889
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103320A AR106536A1 (en) | 2015-10-30 | 2016-10-31 | ANTI-HTRA1 ANTIBODIES AND METHODS OF USE OF THE SAME |
| ARP210100356A AR121317A2 (en) | 2015-10-30 | 2021-02-11 | ANTI-HTRA1 ANTIBODIES AND METHODS OF USE THEREOF |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100356A AR121317A2 (en) | 2015-10-30 | 2021-02-11 | ANTI-HTRA1 ANTIBODIES AND METHODS OF USE THEREOF |
Country Status (1)
| Country | Link |
|---|---|
| AR (2) | AR106536A1 (en) |
-
2016
- 2016-10-31 AR ARP160103320A patent/AR106536A1/en unknown
-
2021
- 2021-02-11 AR ARP210100356A patent/AR121317A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR121317A2 (en) | 2022-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109298A1 (en) | MULTIEPITOPIC AND MULTIVALENT ANTIBODIES THAT HAVE AGONIST ACTIVITY AND METHODS OF USE | |
| AR105026A1 (en) | ANTIBODIES MATURED BY AFFINITY AND HUMANIZED FOR FcRH5 AND METHODS FOR USE | |
| FI3484915T3 (en) | New antibodies that specifically bind to Zika virus epitopes and their uses | |
| MX387662B (en) | HUMANIZED ANTI-HUMAN GROUP OF DIFFERENTIATION 19 (CD19) ANTIBODIES AND METHODS OF USE. | |
| AR076662A1 (en) | ANTI-EGFL7 HUMANIZED ANTIBODIES AND METHODS OF THE SAME USE | |
| AR111249A1 (en) | OPTIMIZED ANTIBODY COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | |
| AR101875A1 (en) | ANTIGENS, BI-SPECIFIC UNION PROTEIN OF THE ANTI-CGRP RECEIVER / PAC1 RECEIVER AND USES OF THE SAME | |
| PE20141562A1 (en) | ANTI-HTRA1 ANTIBODIES AND METHODS OF USE | |
| AR084456A1 (en) | ANTI-PCSK9 ANTIBODY AND METHODS OF USE | |
| JP2020500538A5 (en) | ||
| AR107077A1 (en) | ANTI-C5 ANTIBODIES AND METHODS FOR USE | |
| JP2018064580A5 (en) | ||
| AR091462A1 (en) | ANTI-PCSK9 ANTIBODIES, FORMULATIONS, DOSAGE AND METHODS OF USE | |
| JP2020503001A5 (en) | ||
| JP2018521638A5 (en) | ||
| AR069501A1 (en) | ANTI-VEGF ANTIBODIES (VASCULAR ENDOTELIAL GROWTH FACTOR) | |
| RU2017119543A (en) | ANTI-TIM3 ANTIBODIES AND WAYS OF THEIR APPLICATION | |
| PE20201186A1 (en) | ANTITAU ANTIBODIES AND METHODS OF USE | |
| PE20181363A1 (en) | OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES | |
| AR091701A1 (en) | ANTI-CD22 ANTIBODIES AND IMMUNOCATE PLAYERS | |
| IL273841B1 (en) | Antibodies directed against CD137 and methods of use thereof | |
| JP2012527899A5 (en) | ||
| JP2016538876A5 (en) | ||
| NZ626520A (en) | Anti-lrp5 antibodies and methods of use | |
| PE20190733A1 (en) | ANTIBODIES AGAINST DENGUE VIRUS, POLYPEPTIDES CONTAINING VARIANTS FC REGIONS, AND METHODS OF USE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |